| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2025 , Vol 63 , Num 2
Investigation the selective anticancer activities of montmorillonite and curcumin on the pancreatic and breast cancer
1 Istanbul Medipol University, Complemantary and Traditional Medicine, Istanbul, Türkiye2 Istanbul Medipol University, Molecular Medicine and Biotechnology, Istanbul, Türkiye
3 US Food and Drug Administration, Pharmaceutical Quality, Silver Spring, USA
4 Istanbul Medipol University, Department of Medical History and Deontology, Istanbul, Türkiye
DOI : 10.23893/1307-2080.APS6324 Viewed : 82 - Downloaded : 27 Breast and pancreatic cancers are among the leading causes of death worldwide. In this study, the anticancer activities of natural-based montmorillonite and modified curcumin are examined in pancreatic and breast cancer. MRC-5, PANC-1, and MDA-MB-231 cell lines are used as healthy fibroblast cell lines (control), pancreatic and breast cancer respectively. 10-1000 ?g/mL doses applied to each cell line. As a result, we obtained that montmorillonite has no significant reducing effects on cell viability in the MRC-5 cell line. IC 50 values were 1456 ?g/mL for MDA-MB-231 and 1166 ?g/mL for PANC-1 cells. When modified curcumin therapy doses were applied, IC 50 values were 215 ?g/mL for MRC-5, 56.45 ?g/mL for MDA-MB-231, and 72.34 ?g/mL for PANC-1 cells. In conclusion, this study demonstrates that these two natural compounds have antitumoral effects on pancreatic and breast cancer. These compounds may be useful in the development of natural-based treatments for breast and pancreatic cancer Keywords : Bentonite, montmorillonite, curcumin, pancreatic neoplasms, breast neoplasms